AHUS

Clinical trials for AHUS explained in plain language.

Never miss a new study

Get alerted when new AHUS trials appear

Sign up with your email to follow new studies for AHUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare blood disorder: ravulizumab trial targets platelet recovery

Disease control Recruiting now

This study is testing a drug called ravulizumab in people with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and kidney damage. The main goal is to see if the drug improves platelet counts over 26 weeks. About 20 participants will receive the…

Matched conditions: AHUS

Phase: PHASE4 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control

Last updated May 04, 2026 16:24 UTC

AHUS

Get alerted when new AHUS trials appear

New hope for rare blood disorder: ravulizumab trial targets platelet recovery